P
Peter S. Nelson
Researcher at Fred Hutchinson Cancer Research Center
Publications - 497
Citations - 57568
Peter S. Nelson is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 96, co-authored 425 publications receiving 47923 citations. Previous affiliations of Peter S. Nelson include University of Washington & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Differential Gene Expression in Benign Prostate Epithelium of Men with and without Prostate Cancer: Evidence for a Prostate Cancer Field Effect
Michael C. Risk,Beatrice S. Knudsen,Ilsa Coleman,Ruth Dumpit,Alan R. Kristal,Nolwenn LeMeur,Robert Gentleman,Lawrence D. True,Peter S. Nelson,Daniel W. Lin +9 more
TL;DR: Gene expression profiles between benign epithelia of patients with and without prostate cancer are very similar, however, these tissues exhibit differences in the expression levels of several genes previously associated with prostate cancer development or progression.
Journal ArticleDOI
Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.
Sylvan C. Baca,Sylvan C. Baca,David Y. Takeda,Ji-Heui Seo,Justin H. Hwang,Sheng-Yu Ku,Rand Arafeh,Taylor E. Arnoff,Supreet Agarwal,Connor Bell,Edward P. O’Connor,Xintao Qiu,Sarah Abou Alaiwi,Rosario I. Corona,Marcos A. S. Fonseca,Claudia Giambartolomei,Claudia Giambartolomei,Paloma Cejas,Klothilda Lim,Monica He,Anjali V. Sheahan,Amin Nassar,Jacob E. Berchuck,Lisha G. Brown,Holly M. Nguyen,Ilsa Coleman,Arja Kaipainen,Navonil De Sarkar,Peter S. Nelson,Colm Morrissey,Keegan Korthauer,Mark Pomerantz,Leigh Ellis,Leigh Ellis,Bogdan Pasaniuc,Kate Lawrenson,Kathleen Kelly,Amina Zoubeidi,Amina Zoubeidi,William C. Hahn,William C. Hahn,Himisha Beltran,Henry W. Long,Myles Brown,Eva Corey,Matthew L. Freedman,Matthew L. Freedman +46 more
TL;DR: In this paper, the epigenomic basis of resistance to targeted therapy in cancer was investigated by profiling histone modifications in NEPC and PRAD patient-derived xenografts (PDXs) using chromatin immunoprecipitation and sequencing.
Journal ArticleDOI
Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade
Rana R. McKay,Bruce Montgomery,Wanling Xie,Zhenwei Zhang,Glenn J. Bubley,David W. Lin,Mark A. Preston,Quoc-Dien Trinh,Peter Chang,Andrew A. Wagner,Elahe A. Mostaghel,Philip W. Kantoff,Peter S. Nelson,Adam S. Kibel,Mary-Ellen Taplin +14 more
TL;DR: It is highlighted that neoadjuvant therapy prior to RP in unfavorable intermediate and high-risk patients may potentially have a positive impact on recurrence rates and larger studies with longer follow-up periods are warranted to evaluate the impact of neoad juvant hormone therapy on pathologic and long-term outcomes.
Journal ArticleDOI
Androgen receptor (AR) expression in AR-negative prostate cancer cells results in differential effects of DHT and IGF-I on proliferation and AR activity between localized and metastatic tumors.
Stephen R. Plymate,Stephen R. Plymate,Marie K. Tennant,Stephen H. Culp,Lillie Woodke,Marco Marcelli,Ilsa Colman,Peter S. Nelson,Peter S. Nelson,Julie M. Carroll,Charles T. Roberts,Joy L. Ware +11 more
TL;DR: Two features of the progression from organ‐confined to metastatic prostate cancer are dysregulation of the androgen receptor (AR) and a decrease in insulin‐like growth factor‐type‐I receptor (IGF‐IR) expression.
Journal ArticleDOI
Contribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate Cancer
Elahe A. Mostaghel,Ailin Zhang,Susana A. Hernandez,Brett T. Marck,Xiaotun Zhang,Daniel Tamae,Heather E. Biehl,Maria S. Tretiakova,Jon Bartlett,John Burns,Ruth Dumpit,Lisa S Ang,Alvin M. Matsumoto,Trevor M. Penning,Steven P. Balk,Colm Morrissey,Eva Corey,Lawrence D. True,Peter S. Nelson +18 more
TL;DR: Tumor growth and androgens were suppressed more strongly by surgical ADX than prior studies using abiraterone, suggesting reduction in adrenally-derived androgens beyond that achieved by abirATERone may have clinical benefit.